← All trials
NCT06181760
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2023
- Primary completion
- Jan 20, 2024
- Completion date
- Jan 20, 2024
- First posted
- Dec 26, 2023
- Last posted
- Dec 26, 2023
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Island PharmaceuticalsLead sponsor
- Scientia Clinical Research Limited SydneyOfficial
- Beyond Drug DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.